Table 5.
Subgroup analysis examining the impact of study design, type of ischemic heart disease, timing of transplantation, number of BMCs transplanted, and route of BMC transplantation, and left ventricular ejection fraction at baseline on outcome variables.
| Outcome | Difference in mean (95% confidence interval) | P value for subgroup differences | |
|---|---|---|---|
| Acute MI | Chronic IHD | ||
| LVEF | 3.48 (2.05 to 4.91) | 4.94 (3.27 to 6.61) | 0.19 |
| Infarct scar size | –3.73 (–5.29 to –2.18) | –6.09 (–7.96 to –4.21) | 0.06 |
| LVESV | –5.91 (–8.31 to –3.50) | –16.34 (–23.98 to –8.70) | 0.01 |
| LVEDV | –3.76 (–6.38 to –1.15) | –7.81 (–13.8 to –1.83) | 0.22 |
| Anterior wall MI | MI in any territory | ||
| LVEF | 3.37 (1.48 to 5.26) | 4.37 (2.91 to 5.82) | 0.41 |
| Infarct scar size | –3.56 (–6.28 to –0.84) | –4.85 (–7.27 to –2.42) | 0.49 |
| LVESV | –8.15 (–12.03 to –4.27) | –10.08 (–14.56 to –5.60) | 0.52 |
| LVEDV | –13.73 (–22.2 to –5.27) | –3.14 (–5.87 to –0.41) | 0.02 |
| Baseline LVEF <43 % | Baseline LVEF ≥43% | ||
| LVEF | 4.83 (3.37 to 6.29) | 3.61 (2.05 to 5.18) | 0.26 |
| Infarct scar size | –3.84 (–6.14 to –1.55) | –4.52 (–7.07 to –1.97) | 0.70 |
| LVESV | –13.93 (–18.27 to –9.59) | –4.70 (–7.34 to –2.07) | 0.0004 |
| LVEDV | –10.01 (–14.59 to –5.43) | –2.19 (–6.08 to 1.69) | 0.01 |
| Baseline LVEF <50 % | Baseline LVEF ≥50 % | ||
| LVEF | 4.06 (2.87 to 5.24) | 3.75 (0.81 to 6.69) | 0.85 |
| Infarct scar size | –4.55 (–6.32 to –2.77) | –3.03 (–5.84 to –0.23) | 0.37 |
| LVESV | –9.88 (–12.91 to –6.86) | –4.49 (–8.73 to –0.26) | 0.04 |
| LVEDV | –7.18 (–10.69 to –3.68) | –1.05 (–5.42 to 3.31) | 0.03 |
| BMCs injected <7 d after acute MI and/or PCI | BMCs injected 7 to 30 d after acute MI and/or PCI | ||
| LVEF | 3.91 (1.40 to 6.42) | 0.43 | |
| Infarct scar size | 2.68 (0.87 to 4.48) | –4.78 (–7.91 to –1.64) | 0.55 |
| LVESV | –3.56 (–6.0 to –1.12) | –7.48 (–12.24 to –2.72) | 0.35 |
| LVEDV | –4.89 (–7.48 to –2.3) –7.14 (–12.29 to –1.99) |
–0.12 (–4.48 to 4.24) | 0.04 |
| No. of BMCs <100 × 106 | No. of BMCs ≥100 × 106 | ||
| LVEF | 4.69 (3.22 to 6.16) | 3.54 (2.04 to 5.04) | 0.28 |
| Infarct scar size | –4.35 (–6.45 to –2.25) | –3.71 (–6.65 to –0.78) | 0.73 |
| LVESV | –13.46 (–18.78 to –8.15) | –4.52 (–6.67 to –2.37) | 0.002 |
| LVEDV | –5.1 (–9.45 to –0.76) | –4.52 (–8.30 to –0.75) | 0.84 |
| No. of BMCs <40 × 106 | No. of BMCs ≥40 × 106 | ||
| LVEF | 1.88 (–0.49 to 4.25) | 4.19 (3.06 to 5.32) | 0.09 |
| Infarct scar size | –3.48 (–10.13 to 3.17) | –4.22 (–5.73 to –2.71) | 0.83 |
| LVESV | –13.59 (–32.68 to 5.49) | –7.78 (–10.21 to –5.35) | 0.55 |
| LVEDV | –7.30 (–20.31 to 5.72) | –4.31 (–6.60 to –2.03) | 0.66 |
| BMMNC | CD133+/CD34+ | ||
| LVEF | 3.84 (2.68 to 5.00) | 3.05 (–0.19 to 6.29) | 0.65 |
| Infarct scar size | –3.47 (–4.86 to –2.07) | 0.94 (–2.85 to 4.74) | 0.03 |
| LVESV | –9.13 (–12.08 to –6.17) | –16.53 (–40.47 to 7.41) | 0.55 |
| LVEDV | –6.47 (–9.00 to –3.94) | –8.01 (–25.02 to 9.00) | 0.86 |
| Other Ficoll-based methods | Lymphoprep | ||
| LVEF | 3.94 (2.57 to 5.31) | 4.44 (2.06 to 6.82) | 0.72 |
| Infarct scar size | –3.81 (–5.98 to –1.65) | –2.42 (–2.80 to –2.04) | 0.21 |
| LVESV | –9.75 (–13.83 to –5.68) | –6.46 (–8.88 to –4.05) | 0.17 |
| LVEDV | –7.5 (–11.46 to –3.54) | –9.54 (–27.93 to 8.85) | 0.83 |
| No heparin | Heparinized Saline | ||
| LVEF | 2.58 (1.22 to 3.95) | 6.15 (4.30 to 8.01) | 0.002 |
| Infarct scar size | –4.29 (–6.66 to –1.92) | –4.58 (–6.37 to –2.79) | 0.85 |
| LVESV | –4.84 (–8.4 to –1.27) | –13.07 (–19.17 to –6.96) | 0.02 |
| LVEDV | –6.41 (–12.29 to –0.52) | –4.43 (–7.05 to –1.80) | 0.55 |
| IC - Chronic IHD | IM - Chronic IHD | ||
| LVEF | 3.43 (0.33 to 6.53) | 4.94 (3.27 to 6.12) | 0.40 |
| Infarct scar size | –3.99 (–8.3 to 0.32) | –3.42 (–10.23 to 3.39) | 0.89 |
| LVESV | –19.24 (–37.92 to –0.56) | –15.64 (–24.95 to –6.33) | 0.74 |
| LVEDV | –12.91 (–27.96 to 2.14) | –6.39 (–12.78 to 0.00) | 0.43 |
| RCTs | Cohort studies | ||
| LVEF | 3.35 (2.19 to 4.50) | 5.68 (3.54 to 7.82) | 0.06 |
| Infarct scar size | –3.03 (–4.58 to –1.48) | –6.80 (–9.85 to –3.75) | 0.03 |
| LVESV | –6.58 (–9.30 to –3.86) | –17.50 (–26.20 to –8.80) | 0.02 |
| LVEDV | –4.15 (–6.78 to –1.52) | –8.9 (–15 to –2.81) | 0.16 |
Abbreviations: BMC, bone marrow cells; CIHD, chronic ischemic heart disease; IC, intracoronary; IM, intramyocardial; MI, myocardial infarction; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end-systolic volume; PCI, percutaneous coronary intervention; RCT, randomized controlled trial.